Publications

View and download slide summaries of the latest original articles focusing on therapies in immune-mediated inflammatory diseases including rheumatology, dermatology, and gastroenterology. All materials produced by the team are subsequently reviewed and approved by individual Steering Committee members.

March 2021

Efectos de Un Año de Terapia con Tofacitinib en el Metabolismo Óseo en Artritis Reumatoide

Osteoporos Int 2021 Feb 9 DOI 10.1007/s00198-021-05871-0

Hamar A,

Végh E,

Soós B,

Nagy G,

Tajti G,

Panyi G,

Thought to be the first study of its kind, Hamar, et al. have demonstrated the effect of one-year tofacitinib treatment on bone mineral density (BMD) in RA patients. While the association between RA and osteoporosis is well known, and evidence indicates that up to 70% of these patients have reduced BMD, little information is available on how the JAK inhibitor tofacitinib affects bone status, areal and volumetric BMD, and bone turnover markers. In this prospective study, 30 patients were assessed...

Keywords:

January 2021

Artritis Reumatoide Difícil de Tratar: Definición EULAR

Ann Rheum Dis 2021;80:31–35.

Nagy G,

Hamar A,

Kent A,

A significant proportion of people with RA remain symptomatic despite treatment according to current management recommendations. Different terms have traditionally been used to describe this subpopulation, including severe, refractory, resistant to multiple drugs or treatments, established and difficult-to-treat. A recent survey indicated that – in addition to new drugs – new management approaches are needed for optimal treatment in these patients.A EULAR Task Force agreed the uniform terminolog...

Keywords:

EULAR